Book Value per Share: Pieris Pharmaceuticals (PVLA)

Graphic logo of Pieris Pharmaceuticals (PVLA)

This daily price chart for Pieris Pharmaceuticals (PVLA) illustrates the price action of the asset, which is currently valued at 14.92. The biotech firm is currently undergoing a rigorous internal restructuring and a freeze on projects following the collapse of a key alliance. The business relies on the commercialization of unique protein technologies to combat oncology and asthma. Previously, Pieris Pharmaceuticals (PVLA) developed therapeutic methods in collaboration with the world's largest pharma behemoths.

Pieris Pharma (PVLA): Share Book Value from 07/04/2022 to 10/27/2026

pieris.com - analytical breakdowns and key metrics (PVLA)

- price and consensus price forecast:
Price Chart Pieris Pharmaceuticals Inc|PVLA - Price Target Chart
- market capitalization data:
Market Capitalization Pieris Pharmaceuticals, Inc.|PVLA - Enterprise Value
- book capitalization data:
Net Assets per Single Share Pieris Pharmaceuticals|PVLA - Net Asset Value|Market Capitalization to Book Value Ratio pieris.com|PVLA - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Pieris Pharmaceuticals|PVLA - Long-Term Debt to Capital|Short-Term Debt to Equity Pieris Pharmaceuticals, Inc.|PVLA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Pieris Pharmaceuticals, Inc.
Fundamental company valuation:Pieris Pharmaceuticals Inc - PVLA
Manufactured products of Pieris Pharmaceuticals, Inc.

Book value per share reflects the actual value of the issuer's net assets, excluding market fluctuations. This metric is calculated as the difference between all assets and liabilities, divided by the number of shares. The trend in reference book value per share demonstrates the rate of equity preservation. For Pieris Pharmaceuticals (PVLA), this metric is critical during the restructuring period following the termination of its partnership. It allows for an assessment of the residual value of assets available for licensing to ensure business survival.

Competitors of Pieris Pharmaceuticals (PVLA)

ARGX - Net Assets per Single Share|BNTX - Net Assets per Single Share|ABVX: Book Value per Share|ADMA (admabiologics.com) - Book Value per Share|Net Assets per Single Share Protagonist PTGX|Share Book Value Immunovant Inc|Kiniksa Pharmaceuticals Ltd (KNSA) - Book Value per Share|Accounting Value of a Share Grifols Biemat (GRFS)|Book Value per Share ADPT (Adaptive Biotechnologies)|celldex.com - Book Value per Share|Net Assets per Single Share Aurinia Pharmaceuticals Inc. (AUPH)|BCRX: Accounting Value of a Share|VERA (Vera Pharma) - Net Assets per Single Share|Dianthus Corp (DNTH) - Accounting Value per Share|PHVS (Pharvaris N.V.) - Book Value per Share|Book Value per Share AbCellera Corp (ABCL)|Tourmaline Bio (TRML) - Accounting Value per Share|Accounting Value of a Share Precigen Inc (PGEN)|Book Value per Share PHAR|Nektar Corp - Net Assets per Share|UPB: Net Assets per Single Share|ZBIO: Accounting Value per Share|IMNM (Immunome) - Net Assets per Single Share|Accounting Value per Share Gossamer Bio Inc|KALV (KalVista Pharmaceuticals Inc) - Accounting Value per Share|Book Value per Share SEPN|Net Assets per Single Share Savara Inc. SVRA|Equity per Share rigel.com (RIGL)|ANAB: Book Value per Share|Astria Therapeutics Inc - Net Asset Value per Share|Net Assets per Single Share enGene Bio|RAPT - Share Book Value|aerovatetx.com - Book Value per Share|aclaristx.com (ACRS) - Net Assets per Share|Book Value per Share KYTX (Kyverna Therapeutics, Inc.)|Net Asset Value per Share TLSA|Cabaletta Bio, Inc (CABA) - Net Assets per Single Share|Accounting Value of a Share Ventyx Biosciences, Inc (VTYX)|Book Value per Share THTX|avalotx.com - Net Assets per Share|Net Assets per Single Share ELDN (Eledon Pharmaceuticals, Inc.)|Agenus, Inc. (AGEN) - Net Assets per Share|Accounting Value per Share Climb Bio, Inc. CLYM|ZURA (Zura Bio Ltd) - Accounting Value of a Share|Net Assets per Single Share aTyr Pharma, Inc. ATYR|Share Book Value Adagene Corp|ImageneBio Inc (IMA) - Book Value per Share|Accounting Value of a Share shattucklabs.com (STTK)|Book Value per Share EQ (Equillium)|Connect Biopharma Holdings - Book Value per Share|Net Assets per Single Share Immunic Inc (IMUX)|ATRA: Accounting Value of a Share|IFRX (inflarx.de) - Net Assets per Single Share|X4 Pharmaceuticals Inc. (XFOR) - Accounting Value per Share|ACET (Adicet Bio Inc.) - Book Value per Share|Book Value per Share Celularity Corp|Book Value per Share INMB (INmune Bio, Inc.)|Accounting Value per Share barinthusbio.com (BRNS)|KZR: Book Value per Share|SABS - Net Asset Value per Share|Akari Therapeutics plc - Accounting Value per Share|Enlivex Therapeutics (ENLV) - Book Value per Share|QTTB - Accounting Value per Share|geovax.com (GOVX) - Book Price of a Share|EDSA: Book Value per Share|Net Assets per Share iBio Inc|Book Value per Share CARM (Carisma Therapeutics)|Accounting Value per Share XTL Bio (XTLB)|Book Value per Share BOLT (Bolt Biotherapeutics, Inc.)|HCW Biologics, Inc. - Book Value per Share|APVO - Net Assets per Single Share|AIM: Net Assets per Single Share|aditxt.com - Net Assets per Single Share|GRI (GRI Bio Corporation) - Net Assets per Share|Net Assets per Single Share XORTX Therapeutics Inc. XRTX|Share Book Value reshapelifesciences.com (HIND)|Accounting Value per Share Revelation Biosciences, Inc. (REVB)|Net Assets per Single Share INDP (Indaptus Therapeutics Inc)|Net Assets per Single Share Scinai SCNI|Net Assets per Single Share CalciMedica Inc CALI|Affimed Therapeutics - Book Value per Share|ALLK: Book Value per Share|Net Assets per Single Share hookipapharma.com (HOOK)|IGM Biosciences (IGMS) - Share Book Value|ITOS - Book Value per Share|Accounting Value of a Share Ocean Biomedical Corp|Book Value per Share TCBP|Book Value per Share THRD (thirdharmonicbio.com)